Tetraspanin CD37 protects against the development of B cell lymphoma

Charlotte M. De Winde, Sharon Veenbergen, Ken H. Young, Zijun Y. Xu-Monette, Xiao Xiao Wang, Yi Xia, Kausar J. Jabbar, Michiel Van Den Brand, Alie Van Der Schaaf, Suraya Elfrink, Inge S. Van Houdt, Marion J. Gijbels, Fons A.J. Van De Loo, Miranda B. Bennink, Konnie M. Hebeda, Patricia J.T.A. Groenen, J. Han Van Krieken, Carl G. Figdor, Annemiek B. Van Spriel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Worldwide, B cell non-Hodgkin lymphoma is the most common hematological malignancy and represents a substantial clinical problem. The molecular events that lead to B cell lymphoma are only partially defined. Here, we have provided evidence that deficiency of tetraspanin superfamily member CD37, which is important for B cell function, induces the development of B cell lymphoma. Mice lacking CD37 developed germinal center-derived B cell lymphoma in lymph nodes and spleens with a higher incidence than Bcl2 transgenic mice. We discovered that CD37 interacts with suppressor of cytokine signaling 3 (SOCS3); therefore, absence of CD37 drives tumor development through constitutive activation of the IL-6 signaling pathway. Moreover, animals deficient for both Cd37 and Il6 were fully protected against lymphoma development, confirming the involvement of the IL-6 pathway in driving tumorigenesis. Loss of CD37 on neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlated with activation of the IL-6 signaling pathway and with worse progressionfree and overall survival. Together, this study identifies CD37 as a tumor suppressor that directly protects against B cell lymphomagenesis and provides a strong rationale for blocking the IL-6 pathway in patients with CD37- B cell malignancies as a possible therapeutic intervention.

Original languageEnglish
Pages (from-to)653-666
Number of pages14
JournalJournal of Clinical Investigation
Volume126
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016

Cite this